Streetbeat News

Analyst Ratings

CBAY

Analysts have provided bullish and somewhat bullish ratings for CymaBay Therapeutics (NASDAQ:CBAY) in the last quarter, with an average 12-month price target of $13.6. The average price target has increased by 0.74% over the past month.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:01 pm

SHC

In the last 3 months, 4 analysts have provided somewhat bullish ratings for Sotera Health (NASDAQ:SHC) with an average 12-month price target of $20.75, up 0.39% from the previous average of $20.67.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:01 pm

RVPH

Over the past 3 months, 5 analysts have published their opinion on Reviva Pharmaceuticals (NASDAQ:RVPH) stock, with 4 bullish and 1 somewhat bullish ratings. The company has an average 12-month price target of $15.0, up 50% from the previous average of $10.0.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:01 pm

ALK

Over the past 3 months, 6 analysts have published their opinion on Alaska Air Gr (NYSE:ALK) stock, with an average 12-month price target of $71.5. The current average has decreased by 1.38% from the previous average price target of $72.50.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:00 pm

ALB

BURL

CAMP

GOOG

IONQ

MRCY

PLYA

RDNT

SHW

TSLA

UAL

Several analyst firms have updated their price targets and ratings for various US-listed companies, including RadNet, Albemarle, Tesla, CalAmp, Alphabet, Sherwin-Williams, IonQ, Mercury Systems, Playa Hotels & Resorts, United Airlines, and Burlington Stores.

Portfolio Pulse from Lisa Levin

June 26, 2023 | 1:00 pm

STOK

In the last quarter, Stoke Therapeutics (NASDAQ:STOK) received 5 bullish, 2 somewhat bullish, and 1 indifferent analyst ratings. The average 12-month price target for the stock is $25.5, with a high of $35.00 and a low of $12.00. The average price target has increased by 75.86% over the past month.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 1:00 pm

AMZN

GOOGL

META

MSFT

NVDA

XLK

Wedbush analyst Daniel Ives predicts a tech bull market driven by the AI revolution, with tech stocks expected to rally 12-15% in the second half of the year. He believes the 4th Industrial Revolution is underway and AI spending will increase to 8-10% of overall IT budgets by 2024.

Portfolio Pulse from Shanthi Rexaline

June 26, 2023 | 12:55 pm

CDTX

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 12:55 pm

CBAY

HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and maintains a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 12:54 pm

UNCY

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 12:53 pm